A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis

Trial Profile

A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Rezafungin (Primary) ; Rezafungin (Primary) ; Fluconazole
  • Indications Vulvovaginal candidiasis
  • Focus Adverse reactions
  • Acronyms RADIANT
  • Sponsors Cidara Therapeutics
  • Most Recent Events

    • 21 Feb 2017 Cidara Therapeutics has discontinued the program for the development of topical CD101 based on unfavourable results of this trial, according to a company media release.
    • 21 Feb 2017 Status changed from active, no longer recruiting to discontinued, according to a Cidara Therapeutics media release.
    • 21 Feb 2017 Results published in a Cidara Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top